Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib in Patients With MSS Recurrent or Persistent Endometrial Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02912572
Recruitment Status : Recruiting
First Posted : September 23, 2016
Last Update Posted : July 26, 2019
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Panagiotis Konstantinopoulos, MD, PhD, Dana-Farber Cancer Institute

Brief Summary:
This research study is evaluating a drug called Avelumab as a possible treatment for recurrent or Metastatic Endometrial Cancer.

Condition or disease Intervention/treatment Phase
Metastatic Endometrial Cancer Drug: Avelumab Drug: Talazoparib Phase 2

Detailed Description:

This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. "Investigational" means that the drug is still being studied and that research doctors are trying to find out more about it-such as the safest dose to use, the side effects it may cause, and if the drug is effective for treating different types of cancer. It also means that the FDA (the U.S. Food and Drug Administration) has not yet approved the drug for use in patients, including people with Metastatic Endometrial Cancer.

Avelumab is a drug that may stop cancer cells from growing by enabling the activation of the immune system. Avelumab blocks an immune inhibiting signal that can impair the ability of the immune system to attack cancers.

Talazoparib is a drug that stops the activity of a protein (called PARP) that's involved in repairing damage to the DNA within your cells. When PARP is turned off by Talazoparib in cancer cells, DNA damage cannot be repaired and leads to the death of the cancer cells.

In this research study, the investigators are looking to see whether Avelumab and Talazoparib are effective in treating recurrent and Metastatic Endometrial Cancer.

Additionally, the investigators are looking to see if participants whose tumors contain a particular genetic make-up will have better response to Avelumab or the combination of Avelumab and Talazoparib.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Two-Group, Two-Stage, Open-Label Study of Avelumab (MSB0010718C) in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab (MSB0010718C) /Talazoparib (MDV3800, BMN 673) in Patients With MSS Recurrent or Persistent Endometrial Cancer
Actual Study Start Date : November 14, 2016
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : April 2024

Resource links provided by the National Library of Medicine

Drug Information available for: Avelumab

Arm Intervention/treatment
Experimental: Pole Mutated Endometrial Cancer
Participants with Pole mutated endometrial cancer Avelumab will be administered intravenously twice per cycle
Drug: Avelumab
Avelumab will be administered intravenously twice per cycle Each Cycle lasts 28 days Dosage is determined by physician Premedication Antihistamine and Paracetamol will be administered prior to treatment

Experimental: MSS Endometrial Cancer
Participants with MSS mutated endometrial cancer Avelumab will be administered intravenously twice per cycle
Drug: Avelumab
Avelumab will be administered intravenously twice per cycle Each Cycle lasts 28 days Dosage is determined by physician Premedication Antihistamine and Paracetamol will be administered prior to treatment

Experimental: MSS Avelumab/Talazoparib Combination Arm
Participants with MSS mutated endometrial cancer Avelumab will be administered intravenously twice per cycle Talazoparib will be administered one time per day by mouth
Drug: Avelumab
Avelumab will be administered intravenously twice per cycle Each Cycle lasts 28 days Dosage is determined by physician Premedication Antihistamine and Paracetamol will be administered prior to treatment

Drug: Talazoparib
Talazoparib will be taken one time per day by mouth Each Cycle lasts 28 days




Primary Outcome Measures :
  1. Activity Of Avelumab and Avelumab plus Talazoparib In Patients With Recurrent Or Persistent Endometrial Cancer [ Time Frame: 2 years ]
    As assessed by the frequency of patients who survive progression-free for at least 6 months (PFS6) after initiating therapy or have objective tumor response


Secondary Outcome Measures :
  1. Duration of Progression Free Survival as Assessed by RECIST 1.1 [ Time Frame: 2 years ]
    RECIST - Response Evaluation Criteria in Solid Tumors

  2. Duration of Overall Survival [ Time Frame: 2 years ]
  3. Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0 [ Time Frame: 2 years ]
    As classified by the common terminology criteria for adverse events (CTCAE) version 4.0

  4. Immune-Related Objective Response as Assessed by Immune-Related RECIST (irRECIST) [ Time Frame: 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Participants must be classified into one of two cohorts of recurrent or persistent endometrial cancer of any histology:

The first cohort (MSI/POLE cohort) includes endometrial cancers that are:

--MSI-H as determined by immunohistochemical complete loss of expression (absence of nuclear immunoreactivity) of at least one of the mismatch repair genes MSH2, MSH6, MLH1 and PMS2. This test is now done routinely for every newly diagnosed endometrial cancer patient in most centers in the US.

And/OR:

--POLE-mutated, i.e. endometrial cancers known to harbor mutations in the exonuclease domain (amino acid residues 268-471) of polymerase e (POLE) as determined by targeted sequencing or other next generation sequencing assay. Any Clinical Laboratory Improvement Amendments (CLIA)-approved genomic test documenting mutations in the exonuclease domain of POLE gene (amino acid residues 268-471) in the tumor will be accepted as proof of presence of POLE mutations and will lead to classification into this patient cohort.

The second cohort (MSS cohort) includes:

  • Endometrial cancers that are MSS as determined by normal immunohistochemical nuclear expression of all the mismatch repair genes MSH2, MSH6, MLH1 and PMS2. Tumors which have not been sequenced for POLE mutations (i.e. their POLE mutations status is unknown) but are MSS, will be included in this cohort.

    • All patients must have measurable disease as defined by RECIST 1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be >= 10 mm when measured by CT, MRI or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray. Lymph nodes must be > 15 mm in short axis when measured by CT or MRI.
    • Prior Therapy:
  • There is no upper limit of prior therapies but patients must have had one prior chemotherapeutic regimen for management of endometrial carcinoma. Initial treatment may include chemotherapy, chemotherapy and radiation therapy, and/or consolidation/maintenance therapy. Any platinum based chemotherapy (single agent platinum or any platinum doublet) administered in conjunction with primary radiation as a radio-sensitizer WILL be counted as a systemic chemotherapy regimen. Furthermore, patients who have only received chemotherapy in the adjuvant setting will be eligible for the study.
  • Prior hormonal therapy is allowed.
  • Patients must NOT have received any class of drugs targeted to the PD-1/PD-L1 pathway.
  • Patients must NOT have received any prior PARP inhibitor therapy.

    • Age of 18 or greater years. Because insufficient dosing or adverse event data are currently available on the use of Avelumab in participants < 18 years of age, children are excluded from the study. Endometrial cancer is very rare in the pediatric population.
    • ECOG performance status 0 or 1 (reference Appendix A for ECOG performance status criteria).
    • Availability of a formalin fixed paraffin embedded (FFPE) block of cancer tissue from the original surgery or biopsy or from a biopsy of recurrent disease.
    • Participants must have normal organ and marrow function as defined below:
  • absolute neutrophil count >1,500/mcL
  • platelets >100,000/mcL
  • hemoglobin ≥ 9g/dL
  • total bilirubin within normal institutional limits
  • AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal
  • creatinine within normal institutional limits OR
  • creatinine clearance ≥60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal.

Please note: creatinine clearance (CLCR) should be estimated according to the Cockcroft-Gault formula as:

CLCR={[(140-age) × weight)]/(72 x SCR)} × 0.85 where CLCR (creatinine clearance) is measured in mL/min, age is expressed in years, weight in kilograms (kg), and SCR (serum creatinine) in mg/dL.

NOTE: Patients with moderate renal impairment (defined as an estimated creatinine clearance of 30-59 mL/min) will receive a reduced starting dose of Talazoparib at 0.75 mg PO QD.

  • Participant must not be pregnant or breastfeeding given that avelumab is an agent with unknown effects in pregnancy and breastfeeding and the potential for teratogenesis. Females of childbearing potential are defined as those who are not surgically sterile (i.e., bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or post-menopausal (defined as ≥ 12 months with no menses without an alternative medical cause). Serum pregnancy test (for females of childbearing potential) negative at screening.
  • The effects of avelumab on the developing human fetus are unknown. For this reason and because some immunomodulatory agents are known to be teratogenic, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
  • Toxicities of prior therapy (excepting alopecia and sensory neuropathy) should be resolved to < grade 2 per the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4. All appropriate treatment areas should have access to a copy of the CTCAE version 4. A copy of the CTCAE version 4 can be downloaded from the CTEP website at: http://ctep.cancer.gov.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Participants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
  • Participants who are receiving any other investigational agents.
  • Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
  • History of allergic reactions attributed to avelumab or any component in its formulations, or compounds of similar chemical or biologic composition to avelumab. Known severe hypersensitivity reactions to monoclonal antibodies (Grade ≥ 3 NCI CTCAE v 4.03), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma)
  • Participants with a history of treatment with an anti-PD-1, anti-PD-L1, anti-CTLA-4 or other investigational agents that target immune checkpoint inhibitors.
  • Participants with a history of treatment with a PARP inhibitor.
  • Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness, which may compromise the efficacy of immunostimulatory therapy.
  • Positive test for HBV surface antigen and / or confirmatory HCV RNA (if anti-HCV antibody tested positive)
  • Subjects requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses ≤ 10 mg or 10 mg equivalent prednisone per day
  • Active infection requiring systemic therapy.
  • Current or prior use of immunosuppressive medication within 7 days prior to enrollment with the following exceptions to this exclusion criterion:

    • Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection);
    • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent;
    • Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication).
  • Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible.
  • Prior organ transplantation including allogeneic stem-cell transplantation.
  • Persisting Grade >=2 toxicity related to prior therapy; however, Grade 2 sensory neuropathy is acceptable.
  • Severe gastrointestinal conditions such as clinical or radiological evidence of bowel obstruction within 4 weeks prior to study entry, uncontrolled diarrhea in the last 4 weeks prior to enrollment, or history of inflammatory bowel disease.
  • Uncontrolled intercurrent illness including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.
  • Known alcohol or drug abuse.
  • Individuals with a history of a different malignancy are ineligible except for the following circumstances: Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: breast cancer in situ, cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.
  • All other significant diseases (for example, inflammatory bowel disease, uncontrolled asthma), which, in the opinion of the Investigator, might impair the subject's tolerance of trial treatment.
  • Any psychiatric condition that would prohibit the understanding or rendering of informed consent
  • Vaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02912572


Contacts
Layout table for location contacts
Contact: DFCI Clinical Trials Hotline 877-338-7425

Locations
Layout table for location information
United States, Illinois
University of Chicago Recruiting
Chicago, Illinois, United States, 60637
Contact: Gini Fleming, MD    773-702-6721      
Principal Investigator: Gini Fleming, MD         
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Carolyn Krasner, MD    617-742-4800      
Principal Investigator: Carolyn Krasner, MD         
Beth Israel Deaconess Medical Center Recruiting
Boston, Massachusetts, United States, 02115
Contact: Mary Buss, MD    617-667-4820      
Principal Investigator: Mary Buss, MD         
Dana Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02115
Contact: Panagiotis A Konstantinopoulos, MD, PhD    617-632-5269    Panagiotis_Konstantinopoulos@dfci.harvard.edu   
Principal Investigator: Panagiotis A Konstantinopoulos, MD, PhD         
Sponsors and Collaborators
Dana-Farber Cancer Institute
Pfizer
Investigators
Layout table for investigator information
Principal Investigator: Panagiotis Konstantinopoulos, MD, PhD Dana-Farber Cancer Institute

Layout table for additonal information
Responsible Party: Panagiotis Konstantinopoulos, MD, PhD, MD, PhD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT02912572     History of Changes
Other Study ID Numbers: 16-322
First Posted: September 23, 2016    Key Record Dates
Last Update Posted: July 26, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Panagiotis Konstantinopoulos, MD, PhD, Dana-Farber Cancer Institute:
Endometrial Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Endometrial Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Diseases
Genital Diseases, Female
Talazoparib
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents